Therefore, interpretations of serum-based KYN/TRP ratios should consider contributions from both IDO and TDO activities, highlighting the importance of integrating other pathway metabolites for a comprehensive assessment of kynurenine pathway flux in AMD patients [27]. This evidence concerns the gene TDO2 and age-related macular degeneration.